Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia

The purpose of this study is to investigate the benefits of giving filled prescription of a medication to be used upon early onset of symptoms of URTI induced asthma. The hope is to reduce the need to present to Health Care centres for treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Upper Respiratory Tract Infection Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Infections Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases Respiratory Tract Infections

Age range

12 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

BC Children's Hospital

Vancouver, British Columbia, V6H 3V4, Canada

About this study

In Canada, asthma affects more the 12% of children. Exacerbation are a common feature of asthma. In children, upper respiratory tract infection (URTI's) are responsible for over 80% of asthma exacerbation.

Experts in asthma care acknowledge this critical problem and have developed guidelines to reduce asthma exacerbation.

The criteria for participation in this study to have 2 or more presentations to a Health Service centre in the past 12 months for URTI induced asthma. These patients will be followed and interviewed monthly over a 12 month period to investigate whether the use of Oral cortico-steroids upon early onset of URTI induced asthma prevents the need for presentation to hospital

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

2 or more presentations to Emergency department in a 12 month period

Exclusion criteria

less then 2 presentations to Emergency department in a 12 month period

Treatment and study plan

Arm 1 Oral Cortico Steroids

Drug

Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.

Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )

Other names: Prednisone

Primary outcomes

Reduction of representation to Health Services for Exacerbation of URTI induced asthma

Time frame: One year

To review the effect of medication given at early onset of symptoms have on reducing the presentation to Health Services and Emergency Departments.

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Registry information

Important dates

Study start: 2011
Primary completion: 2012
Study completion: 2021
First posted: Mar 31, 2011
Registry last updated: May 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed